Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Automated microscopy and image analysis
Real-time, label free cell analysis
Nano and micro particle analysis

Accelerate to discover
Related topics
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Nov 30, 2021
Microfluidics have revolutionized...
Nov 10, 2021
Join our webinar to learn how...
Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing
Oct 11, 2021
Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...
Blood-Brain Barrier (BBB) - Pathophysiology in ischemic stroke
Aug 27, 2021
In-depth Understanding of Blood-Brain Barrier (BBB)
Aug 19, 2021
Year after year, the Micro-CT User meeting showcases state-of-the-art applications in both life and material sciences,...
Predicting single-cell gene expression with imaging flow cytometry data and machine learning
Aug 10, 2021
High-content imaging and single-cell genomics are two of the most prominent high-throughput technologies for studying...
Jul 10, 2017
Wednesday, July 12, 2017, 9 pm CEST.
Dan MacLeod Ph.D., Precision BioSciences, Inc.
At Precision BioSciences, we have developed an allogeneic method using our proprietary ARCUS gene-editing technology to generate “universal” CAR T cells from healthy donors. These cells are engineered to eliminate expression of the endogenous T cell receptor making them safe for transfer to unrelated patients. By integrating the CAR transgene at a single genomic site, we can tightly control the level of CAR expression on the cell surface. We further optimize the cells by designing new CAR T constructs that include modifications to the extracellular binding domains as well as the intracellular signaling domains. Evaluating the impact of these new modifications requires sensitive methods to assay CAR T cell function. Traditional methods for evaluating cytotoxicity cannot effectively predict in vivo activity of a CAR T product; this is because they assess short-term killing potential rather than the ability to expand, persist, and exhibit serial killing. We have used the ACEA xCELLigence instrument for both B Cell Killing Assays and Leukemic Cell Killing Assays to test multiple CAR constructs with modified ectodomains, endodomains, and other modifications, and we have found this platform sensitive enough to detect subtle yet significant differences in performance not observed in traditional killing assays. Furthermore, the sensitivity of the instrument has enabled us to evaluate CAR constructs using cell numbers that are orders of magnitude lower than other assays, greatly enhancing our throughput and capabilities.
Related technologies: Real-time, label free cell analysis
Get more info
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com